

Guillaume Robert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5434759/publications.pdf>

Version: 2024-02-01

67
papers

3,307
citations

172207

29
h-index

143772

57
g-index

69
all docs

69
docs citations

69
times ranked

8505
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1. <i>Cancer Research</i> , 2011, 71, 4366-4372.	0.4	545
2	Resveratrol Promotes Autophagic Cell Death in Chronic Myelogenous Leukemia Cells via JNK-Mediated p62/SQSTM1 Expression and AMPK Activation. <i>Cancer Research</i> , 2010, 70, 1042-1052.	0.4	335
3	Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. <i>Cell Death and Disease</i> , 2011, 2, e199-e199.	2.7	250
4	IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. <i>Scientific Reports</i> , 2018, 8, 256.	1.6	149
5	SPARC Represses E-Cadherin and Induces Mesenchymal Transition during Melanoma Development. <i>Cancer Research</i> , 2006, 66, 7516-7523.	0.4	145
6	Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. <i>Blood</i> , 2012, 119, 4527-4531.	0.6	123
7	Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. <i>Oncotarget</i> , 2011, 2, 874-885.	0.8	99
8	Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. <i>Autophagy</i> , 2009, 5, 1092-1098.	4.3	92
9	The PRKAA1/AMPK \pm 1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. <i>Autophagy</i> , 2015, 11, 1114-1129.	4.3	86
10	Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death. <i>PLoS ONE</i> , 2009, 4, e7889.	1.1	79
11	BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. <i>Oncotarget</i> , 2012, 3, 490-501.	0.8	75
12	HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. <i>Oncogene</i> , 2005, 24, 1423-1433.	2.6	71
13	Targeting autophagy to fight hematopoietic malignancies. <i>Cell Cycle</i> , 2010, 9, 3470-3478.	1.3	70
14	Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells by Inducing Senescence-like Growth Arrest. <i>Cancer Research</i> , 2009, 69, 2748-2756.	0.4	69
15	Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC. <i>Cancer Research</i> , 2010, 70, 9659-9670.	0.4	56
16	Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis. <i>Ultrasonics Sonochemistry</i> , 2012, 19, 1132-1138.	3.8	56
17	Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate. <i>European Neuropsychopharmacology</i> , 2014, 24, 1229-1239.	0.3	56
18	Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. <i>Haematologica</i> , 2013, 98, e20-e22.	1.7	53

#	ARTICLE	IF	CITATIONS
19	Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling Pathway. <i>Journal of Investigative Dermatology</i> , 2007, 127, 400-410.	0.3	51
20	Modulation of the ATM/autophagy pathway by a G-quadruplex ligand tips the balance between senescence and apoptosis in cancer cells. <i>Nucleic Acids Research</i> , 2019, 47, 2739-2756.	6.5	50
21	Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1989-1992.	1.0	47
22	The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death. <i>Autophagy</i> , 2012, 8, 637-649.	4.3	45
23	Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR α -ABL cleavage and elimination of chronic myelogenous leukemia cells. <i>Leukemia</i> , 2010, 24, 115-124.	3.3	43
24	The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. <i>Oncotarget</i> , 2014, 5, 6252-6266.	0.8	43
25	In Vitro and in Vivo Evaluation of Fully Substituted		

#	ARTICLE	IF	CITATIONS
37	A New Hydroxylated Nonaprenylhydroquinone from the Mediterranean Marine Sponge <i>Sarcotragus spinosulus</i> . <i>Marine Drugs</i> , 2011, 9, 1210-1219.	2.2	20
38	The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production. <i>Cell Death and Differentiation</i> , 2012, 19, 1769-1778.	5.0	19
39	BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 47103-47109.	0.8	19
40	FeCl ₃ -promoted and ultrasound-assisted synthesis of resveratrol O-derived glycoside analogs. <i>Ultrasonics Sonochemistry</i> , 2015, 22, 15-21.	3.8	18
41	Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. <i>Oncoscience</i> , 2014, 2, 44-49.	0.9	18
42	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. <i>Oncotarget</i> , 2014, 5, 4384-4391.	0.8	17
43	Caspase 1/11 Deficiency or Pharmacological Inhibition Mitigates Psoriasis-Like Phenotype in Mice. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1306-1317.	0.3	16
44	Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death. <i>Oncotarget</i> , 2016, 7, 26120-26136.	0.8	14
45	Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?. <i>Autophagy</i> , 2019, 15, 927-929.	4.3	12
46	Ultrasound-assisted one-pot three-component synthesis of new isoxazolines bearing sulfonamides and their evaluation against hematological malignancies. <i>Ultrasonics Sonochemistry</i> , 2021, 78, 105748.	3.8	12
47	Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. <i>Oncotarget</i> , 2012, 3, 1688-1699.	0.8	11
48	Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma. <i>Cancer Research</i> , 2021, 81, 3806-3821.	0.4	9
49	The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim. <i>Oncogene</i> , 2018, 37, 2122-2136.	2.6	8
50	Modular synthesis of new C-aryl-nucleosides and their anti-CML activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1931-1936.	1.0	8
51	Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 164.	1.8	8
52	Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines. <i>Cell Cycle</i> , 2013, 12, 1645-1646.	1.3	7
53	Hearing Loss During Osteosarcoma Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e100-e102.	0.3	6
54	Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. <i>European Journal of Haematology</i> , 2020, 104, 488-498.	1.1	6

#	ARTICLE	IF	CITATIONS
55	A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function. <i>Cell Death and Disease</i> , 2014, 5, e1349-e1349.	2.7	5
56	How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments. <i>Current Pharmaceutical Design</i> , 2013, 19, 5362-5373.	0.9	3
57	Reprogramming monocyte-derived macrophages through caspase inhibition. <i>Oncolmmunology</i> , 2022, 11, 2015859.	2.1	3
58	BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients. <i>Blood</i> , 2012, 120, 701-701.	0.6	2
59	ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines. <i>Oncotarget</i> , 2018, 9, 10920-10933.	0.8	2
60	Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines. <i>Blood</i> , 2010, 116, 1817-1817.	0.6	1
61	Autophagy and blood diseases. <i>Hematologie</i> , 2015, 21, 107-116.	0.0	0
62	Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1568-1568.	0.6	0
63	The P2Y6-AMPK Pathway Triggers Autophagy during CSF-1-Induced Human Monocyte Differentiation and Is a Potential Target in CMML. <i>Blood</i> , 2014, 124, 4347-4347.	0.6	0
64	BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3261-3261.	0.6	0
65	Involvement of autophagy in cellular development and differentiation. <i>Hematologie</i> , 2015, 21, 212-220.	0.0	0
66	Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma. <i>Blood</i> , 2015, 126, 2958-2958.	0.6	0
67	Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2840-2840.	0.6	0